Tech Transfer eNews Blog

U of Houston start-up aims to commercialize intranasal COVID-19 vaccine

By Jesse Schwartz
Published: October 14th, 2020

A University of Houston (UH) start-up aims to commercialize a novel intranasal vaccine for COVID-19. The start-up, AuraVax, has entered into an exclusive license option agreement with the university to accelerate the vaccine from the lab to the marketplace.

“We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine platform to address a multitude of respiratory viruses, starting with COVID-19,” says Navin Varadarajan, professor at the UH and co-founder of AuraVax.

“The race for more effective ways of vaccinating against COVID-19 and other respiratory diseases has led to a broad and extensive focus on various protective mechanisms of action,” adds Varadarajan. “Based on preclinical work, our technology not only elicits a mucosal immune response, but also systemic immunity. We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution,”

Amr Elnashai, UH vice president for research and technology transfer, comments, “AuraVax, being created by a UH professor, is the ideal partner for us, and what better cause than to advance the creation of a vaccine to COVID-19, arguably the primary challenge facing our generation. The partnership has my wholehearted support.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment